eprintid: 10176363
rev_number: 8
eprint_status: archive
userid: 699
dir: disk0/10/17/63/63
datestamp: 2023-09-08 09:57:31
lastmod: 2023-09-08 09:58:36
status_changed: 2023-09-08 09:57:31
type: article
metadata_visibility: show
sword_depositor: 699
creators_name: Moody, WE
creators_name: Turvey-Haigh, L
creators_name: Knight, D
creators_name: Coats, CJ
creators_name: Cooper, RM
creators_name: Schofield, R
creators_name: Robinson, S
creators_name: Harkness, A
creators_name: Oxborough, DL
creators_name: Gillmore, JD
creators_name: Whelan, C
creators_name: Augustine, DX
creators_name: Fontana, M
creators_name: Steeds, RP
title: British Society of Echocardiography guideline for the transthoracic echocardiographic assessment of cardiac amyloidosis
ispublished: pub
divisions: UCL
divisions: B02
divisions: C10
divisions: D17
divisions: G90
keywords: Cardiac amyloidosis, Echocardiography, Light chain amyloid cardiomyopathy, Transthyretin amyloid cardiomyopathy
note: © 2023 BioMed Central Ltd. This article is licensed under a Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/).
abstract: These guidelines form an update of the BSE guideline protocol for the assessment of restrictive cardiomyopathy (Knight et al. in Echo Res Prac, 2013). Since the original recommendations were conceived in 2013, there has been an exponential rise in the diagnosis of cardiac amyloidosis fuelled by increased clinician awareness, improvements in cardiovascular imaging as well as the availability of new and effective disease modifying therapies. The initial diagnosis of cardiac amyloidosis can be challenging and is often not clear-cut on the basis of echocardiography, which for most patients presenting with heart failure symptoms remains the first-line imaging test. The role of a specialist echocardiographer will be to raise the suspicion of cardiac amyloidosis when appropriate, but the formal diagnosis of amyloid sub-type invariably requires further downstream testing. This document seeks to provide a focused review of the literature on echocardiography in cardiac amyloidosis highlighting its important role in the diagnosis, prognosis and screening of at risk individuals, before concluding with a suggested minimum data set, for use as an aide memoire when reporting.
date: 2023
date_type: published
publisher: Springer Science and Business Media LLC
official_url: https://doi.org/10.1186/s44156-023-00028-7
oa_status: green
full_text_type: pub
language: eng
primo: open
primo_central: open_green
verified: verified_manual
elements_id: 2082687
doi: 10.1186/s44156-023-00028-7
medium: Electronic
pii: 10.1186/s44156-023-00028-7
lyricists_name: Gillmore, Julian
lyricists_id: JGILL78
actors_name: Flynn, Bernadette
actors_id: BFFLY94
actors_role: owner
full_text_status: public
publication: Echo Research & Practice
volume: 10
number: 1
article_number: 13
event_location: England
citation:        Moody, WE;    Turvey-Haigh, L;    Knight, D;    Coats, CJ;    Cooper, RM;    Schofield, R;    Robinson, S;                             ... Steeds, RP; + view all <#>        Moody, WE;  Turvey-Haigh, L;  Knight, D;  Coats, CJ;  Cooper, RM;  Schofield, R;  Robinson, S;  Harkness, A;  Oxborough, DL;  Gillmore, JD;  Whelan, C;  Augustine, DX;  Fontana, M;  Steeds, RP;   - view fewer <#>    (2023)    British Society of Echocardiography guideline for the transthoracic echocardiographic assessment of cardiac amyloidosis.                   Echo Research & Practice , 10  (1)    , Article 13.  10.1186/s44156-023-00028-7 <https://doi.org/10.1186/s44156-023-00028-7>.       Green open access   
 
document_url: https://discovery.ucl.ac.uk/id/eprint/10176363/1/s44156-023-00028-7.pdf